In a recent study published in Neuropsychopharmacology, researchers from the University of Technology Sydney (UTS) found that inflammation in a key decision-making region of the brain led to more deliberate behavior, rather than more compulsive actions.
In a recent study published in Communications Biology, researchers from Hong Kong, Singapore, and Germany used high-resolution brain imaging to show that psychedelics may redirect visual processing toward memory-related regions.
Recent research from the University of Liège is offering new insight into that question, suggesting a deeper relationship between language and awareness than previously understood.
Researchers from Princeton University have successfully demonstrated a photonic neuromorphic computing architecture capable of performing high-frequency trading tasks at the speed of light, offering a theoretical competitive advantage in the stock market.
A new study from Monash University, published in Genomic Press Psychedelics, found that psilocybin changes social behavior and immune signaling in female mice.
Scientists say combining a low-dose of THC with a common anti-inflammatory drug improved cognition and reduced Alzheimer’s-related brain changes in mice.
A new clinical handbook, Working with Dissociation in Clinical Practice, by Helena Crockford, Melanie Goodwin, and Paul Langthorne, explains that dissociation is more than a brief loss of focus or a rare mental health condition.
Although researchers can monitor brain activity associated with perception, pain, and awareness, it remains unclear which neural pathways are tied to the origins of consciousness.
Laboratory tests of a novel serotonin-binding compound have revealed an unexpected disconnect between receptor activation and behavior, raising new questions about how psychedelic effects emerge in the brain.
New research reveals how psilocybin reshapes connections across the brain, helping explain how it can ease depression symptoms for weeks or even months.
More than half of Americans, roughly 54% of the population, are living with a neurological disease or disorder, according findings detailed in a new study.
Spanish brain-computer interface (BCI) company INBRAIN Neuroelectronics has announced its collaboration with Microsoft to explore AI applications for real-time brain-computer interface therapeutics.
Scientists have found that immersive virtual reality may offer a way to replicate some of the psychological benefits associated with psychedelic substances, but without the use of any drugs.
Neuralink has moved to validate its controversial brain-implant technology in the scientific arena by submitting its first study for peer review and publication.
INBRAIN Neuroelectronics has partnered with Mayo Clinic to advance graphene-based brain-computer interface therapies, expanding into the U.S. while navigating differing European and FDA regulatory pathways.
The rapidly expanding brain-computer interface (BCI) field is not only driving cutting-edge neuroscience but also fueling a competitive race for market dominance.